Adding 11C-methionine PET to the EORTC Prognostic Factors in Grade 2 Gliomas

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2007 Aug 22

PMID 17710394

Citations 16

Authors

A Smits

E Westerberg

D Ribom

Affiliations

Soon will be listed here.

Abstract

Purpose: The management of adult patients with grade 2 gliomas remains a challenge for the clinical neuro-oncologist. Several clinical prognostic factors appear to be as important as treatment factors in determining outcome. From the European Organisation for Research and Treatment of Cancer (EORTC) trials 22844 and 22845, a prognostic scoring system has been proposed based on the presence of unfavourable prognostic factors. The aim of the present study was to assess the additional prognostic value of (11)C-methionine (MET) measured by positron emission tomography (PET) in the setting of the EORTC prognostic scoring system.

Methods: In this retrospective review, 129 patients with supratentorial grade 2 gliomas were subjected to a PET study as part of the pre-treatment tumour investigation. One hundred and three cases were classified as low-risk patients (0-2 unfavourable factors) and 26 cases as high-risk patients (3-5 unfavourable factors) according to the EORTC criteria. MET PET was evaluated as an extra prognostic factor in both groups.

Results: In the high-risk group, patients with high MET uptake had a worse outcome than patients with low MET uptake. A similar trend was found for the low-risk group in patients with oligodendrocytic tumours.

Conclusions: Our findings further strengthen the role of MET PET as an important prognostic tool in the management of this group of patients.

Citing Articles

[11C]-methionine positron emission tomography in the evaluation of pediatric low-grade gliomas.

Kim E, Vavere A, Snyder S, Chiang J, Li Y, Patni T Neurooncol Adv. 2024; 6(1):vdae056.

PMID: 38680989 PMC: 11055465. DOI: 10.1093/noajnl/vdae056.

Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.

Ninatti G, Sollini M, Bono B, Gozzi N, Fedorov D, Antunovic L Neuro Oncol. 2022; 24(9):1546-1556.

PMID: 35171292 PMC: 9435504. DOI: 10.1093/neuonc/noac040.

Prognostic Value of the Metabolic and Volumetric Parameters of C-Methionine Positron-Emission Tomography for Gliomas: A Systematic Review and Meta-Analysis.

Kim Y, Kim Y, Lee J, Jang S AJNR Am J Neuroradiol. 2018; 39(9):1629-1634.

PMID: 29954817 PMC: 7655266. DOI: 10.3174/ajnr.A5707.

Amino acid tracers in PET imaging of diffuse low-grade gliomas: a systematic review of preoperative applications.

Naslund O, Smits A, Forander P, Laesser M, Bartek Jr J, Gempt J Acta Neurochir (Wien). 2018; 160(7):1451-1460.

PMID: 29797098 PMC: 5995993. DOI: 10.1007/s00701-018-3563-3.

Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.

Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug A, Wilhelm D Neuro Oncol. 2017; 20(3):411-419.

PMID: 29016947 PMC: 5817953. DOI: 10.1093/neuonc/nox177.

References

Ribom D, Eriksson A, Hartman M, Engler H, Nilsson A, Langstrom B . Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. Cancer. 2001; 92(6):1541-9. DOI: 10.1002/1097-0142(20010915)92:6<1541::aid-cncr1480>3.0.co;2-d. View

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

Bell D, Grant R, Collie D, Walker M, Whittle I . How well do radiologists diagnose intracerebral tumour histology on CT? Findings from a prospective multicentre study. Br J Neurosurg. 2003; 16(6):573-7. View

Berger M, Deliganis A, Dobbins J, Keles G . The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994; 74(6):1784-91. DOI: 10.1002/1097-0142(19940915)74:6<1784::aid-cncr2820740622>3.0.co;2-d. View

Bergstrom M, Lundqvist H, Ericson K, Lilja A, Johnstrom P, Langstrom B . Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography. Acta Radiol. 1987; 28(3):225-9. View

Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B . Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys. 1999; 45(4):923-9. DOI: 10.1016/s0360-3016(99)00284-9. View

Keles G, Lamborn K, Berger M . Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001; 95(5):735-45. DOI: 10.3171/jns.2001.95.5.0735. View

Shaw E, Arusell R, Scheithauer B, OFallon J, ONeill B, Dinapoli R . Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002; 20(9):2267-76. DOI: 10.1200/JCO.2002.09.126. View

Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P . Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol. 2002; 20(8):2076-84. DOI: 10.1200/JCO.2002.08.121. View

10.

Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F . Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006; 104(2):238-53. DOI: 10.3171/jns.2006.104.2.238. View

11.

van den Bent M, Stupp R, Brandes A, Lacombe D . Current and future trials of the EORTC brain tumor group. Onkologie. 2004; 27(3):246-50. DOI: 10.1159/000077974. View

12.

Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus R . 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998; 50(5):1316-22. DOI: 10.1212/wnl.50.5.1316. View

13.

Karim A, Maat B, Hatlevoll R, Menten J, Rutten E, Thomas D . A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys. 1996; 36(3):549-56. DOI: 10.1016/s0360-3016(96)00352-5. View

14.

Armstrong C, Hunter J, Ledakis G, Cohen B, Tallent E, Goldstein B . Late cognitive and radiographic changes related to radiotherapy: initial prospective findings. Neurology. 2002; 59(1):40-8. DOI: 10.1212/wnl.59.1.40. View

15.

De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M . Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001; 95(5):746-50. DOI: 10.3171/jns.2001.95.5.0746. View

16.

Postma T, Klein M, Verstappen C, Bromberg J, Swennen M, Langendijk J . Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology. 2002; 59(1):121-3. DOI: 10.1212/wnl.59.1.121. View

17.

Ribom D, Engler H, Blomquist E, Smits A . Potential significance of (11)C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging. 2002; 29(5):632-40. DOI: 10.1007/s00259-002-0762-0. View

18.

Daumas-Duport C . Histological grading of gliomas. Curr Opin Neurol Neurosurg. 1992; 5(6):924-31. View

19.

Stupp R, Janzer R, Hegi M, Villemure J, Mirimanoff R . Prognostic factors for low-grade gliomas. Semin Oncol. 2004; 30(6 Suppl 19):23-8. DOI: 10.1053/j.seminoncol.2003.11.029. View

20.

Ohgaki H, Kleihues P . Epidemiology and etiology of gliomas. Acta Neuropathol. 2005; 109(1):93-108. DOI: 10.1007/s00401-005-0991-y. View